Candriam S.C.A. Nuvation Bio Inc. Transaction History

Candriam S.C.A.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$0.29 - $4.04 $52,442 - $730,573	-180,835 Reduced 56.34%	140,129 $314,000
Q1 2022 May 13, 2022	BUY	$4.6 - $8.83 $115,133 - $221,006	25,029 Added 8.46%	320,964 $1.69 Million
Q4 2021 Feb 10, 2022	BUY	$7.75 - $10.05 $68,479 - $88,801	8,836 Added 3.08%	295,935 $2.52 Million
Q3 2021 Nov 09, 2021	BUY	$7.78 - $10.0 $2.23 Million - $2.87 Million	287,099 New	287,099 $2.85 Million

152

123M

9.7K

6.5K

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $480M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.